8-K: HeartCore Enterprises Secures Nasdaq Listing Extension Amidst Equity Deficiency

HeartCore Enterprises, Inc. has received an extension from Nasdaq until September 30, 2025, to regain compliance with the minimum stockholders' equity requirement, supported by new financing agreements totaling up to $27 million.

Summary

• HeartCore Enterprises, Inc. (HTCR) received a notice from Nasdaq on May 24, 2025, indicating non-compliance with the $2,500,000 minimum stockholders' equity requirement (Nasdaq Listing Rule 5550(b)).
• The company also did not meet alternative listing requirements based on market value of listed securities or net income from continuing operations as of May 23, 2025.
• HeartCore submitted a plan to Nasdaq by the July 8, 2025, deadline.
• On July 11, 2025, Nasdaq granted an extension, requiring the company to complete 'Financing Transactions' and evidence compliance by September 30, 2025.
• The 'Financing Transactions' include an Equity Purchase Agreement (ELOC) with Crom Structured Opportunities Fund I, LP, allowing the company to sell up to $25,000,000 in common stock.
• The ELOC is subject to a 19.99% issuance limit until a resale registration statement is declared effective by the SEC, though stockholder approval for the issuance was obtained on June 30, 2025.
• The 'Financing Transactions' also include a Private Placement via a Securities Purchase Agreement (SPA) with the same investor, which closed on June 30, 2025.
• Under the SPA, the investor purchased 2,000 shares of Series A Convertible Preferred Stock at $1,000 per share, totaling $2,000,000, with each share having a stated value of $1,100.
• In connection with the SPA, the company issued 750,000 shares of common stock (SPA Commitment Shares) to the investor for no additional consideration.
• The company will file registration statements covering the resale of shares from both the ELOC and the SPA.
• An Information Statement on Schedule 14C describing the 20% Issuance will be filed and mailed to stockholders, becoming effective no earlier than 20 calendar days after mailing.

Sentiment

Score: 4

Explanation: The company is in a challenging position due to non-compliance with Nasdaq listing rules, indicating underlying financial weakness. While securing an extension and financing agreements provides a lifeline, significant execution risk remains, and the capital raise will lead to substantial dilution for existing shareholders. The outcome is uncertain.

Positives

• Received an extension from Nasdaq until September 30, 2025, to regain compliance, avoiding immediate delisting.
• Secured financing agreements (ELOC and Private Placement) totaling up to $27,000,000, providing a pathway to address the equity deficiency.
• Obtained necessary stockholder approval on June 30, 2025, for the issuance of shares exceeding 19.99% of outstanding common stock.

Negatives

• The company is currently non-compliant with Nasdaq's $2,500,000 minimum stockholders' equity requirement.
• Failed to meet alternative listing standards based on market value of listed securities or net income from continuing operations.
• The financing involves the issuance of new common stock and convertible preferred stock, which will lead to significant shareholder dilution.
• There is no assurance that the company will be able to regain compliance by the extended deadline.

Risks

• There is no assurance that the company will be able to regain compliance with the Minimum Stockholders Equity Requirement by September 30, 2025.
• The effectiveness of the resale registration statements for the Advance Shares, Conversion Shares, and SPA Commitment Shares is required before the full capital can be raised or shares can be resold.
• Failure to maintain compliance with other Nasdaq listing requirements could still lead to delisting.

Future Outlook

The company must complete the Financing Transactions and evidence compliance with Nasdaq's minimum stockholders' equity requirement by September 30, 2025. This involves the potential issuance of up to $25 million in common stock and the conversion of $2 million in preferred stock, contingent on SEC effectiveness of resale registration statements. An Information Statement on Schedule 14C will be filed and mailed to stockholders, with a 20-day waiting period before effectiveness.

Management Comments

• The company has duly caused this report to be signed on its behalf by Sumitaka Yamamoto, Chief Executive Officer.

Industry Context

This announcement primarily addresses a company-specific compliance issue with Nasdaq listing requirements, rather than reflecting broader industry trends. The need for a capital raise to meet equity thresholds is a common challenge for smaller or developing public companies facing financial pressures.

Corporate Governance

Stakeholder Impact

• Shareholders face potential significant dilution due to the issuance of new common stock and convertible preferred stock under the financing agreements.
• Shareholders benefit from the extension granted by Nasdaq, which provides an opportunity for the company to regain compliance and maintain its listing on the Nasdaq Capital Market.
• The company's ability to continue operations and meet its financial obligations is supported by the potential capital infusion.

Next Steps

• Complete the Financing Transactions (ELOC and Private Placement) by September 30, 2025.
• Evidence compliance with the Nasdaq Minimum Stockholders Equity Requirement by September 30, 2025.
• File a registration statement covering the resale of all shares acquired by the investor under the Equity Purchase Agreement and Securities Purchase Agreement.
• File and mail an Information Statement on Schedule 14C to stockholders, describing the 20% Issuance, which will become effective no earlier than 20 calendar days after mailing.

Key Dates

Keywords

HeartCore Enterprises, HTCR, Nasdaq, SEC Filing, 8-K, Listing Compliance, Stockholders Equity, Equity Purchase Agreement, Private Placement, Convertible Preferred Stock, Capital Raise, Dilution, Corporate Governance